Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study

Ribociclib delays pain progression by ~7 months while preserving physical function

MONALEESA-3 QoL analysis: Addition of targeted therapy extends Time to Definitive Deterioration (TTD) across all key domains versus placebo.

Design · Phase III Randomized Controlled Trial (MONALEESA-3) N · 726 Population · HR+/HER2- advanced breast cancer patients Duration · Median follow-up: 20.4 months Arms · Ribociclib + Fulvestrant vs. Placebo + Fulvestrant double-blind placebo-controlled QoL secondary endpoints

Key Performance Indicators

PRIMARY
Pain Deterioration Risk
0.77
Hazard Ratio (95% CI: 0.57–1.05)
23% risk reduction in pain worsening
Physical Function Risk
0.82
Hazard Ratio (95% CI: 0.61–1.10)
18% risk reduction in physical decline
Global Health Risk
0.81
Hazard Ratio (95% CI: 0.62–1.1)
19% risk reduction in overall health decline
1

Consistent Risk Reduction Across Quality of Life Domains

Hazard Ratios consistently favor the Ribociclib arm (<1.0) across Pain, Physical Functioning, and Global Health. Although confidence intervals cross unity, the trend indicates a uniform delay in deterioration across all measured patient-reported outcomes.

2

Months Gained: Time to Definitive Deterioration (TTD)

Patients on Ribociclib experienced a substantial extension in time before clinically significant deterioration occurred. Most notably, the onset of severe pain was delayed by 6.8 months compared to the placebo arm.

3

The 'Lift': Improvement in Deterioration Timelines by Domain

Visualizing the shift from Placebo (left) to Ribociclib (right). Every QoL domain shows an upward trajectory, demonstrating that the addition of the drug systematically pushes back the timeline of patient decline.

4

Physical Functioning: Mean Months to Deterioration

Specific focus on physical capability. The Ribociclib arm maintained physical functioning for nearly 39 months on average, compared to roughly 35 months for placebo, preserving patient independence for longer.

Editorial Conclusion

"Ribociclib plus fulvestrant offers a 'double benefit' strategy: extending progression-free survival while simultaneously delaying the deterioration of pain and physical function by over half a year."
Pain deterioration delayed by 6.8 months (Median 42.7 vs 35.9).
Consistent hazard ratios (0.77–0.82) favoring treatment across all QoL domains.
Baseline QoL scores were balanced, confirming the divergence is treatment-driven.
Clinical Implication
Clinicians can prescribe this regimen with confidence that the added efficacy does not come at the cost of accelerated quality-of-life decline; rather, it preserves patient well-being longer than fulvestrant monotherapy.

Reference Data & Sources

Complete Data Table

Abbreviations

HR = Hazard Ratio · CI = Confidence Interval · TTD = Time to Definitive Deterioration · QoL = Quality of Life

Source

Fasching et al. The Breast 54 (2020) 148-154
DOI: 10.1016/j.breast.2020.09.008

Limitations

Differences were not statistically significant (CIs cross 1.0) No post-progression PRO assessments performed

Provenance Index

Selected: none

AI edit element

Describe the change you want. Optional: attach an image.
No image attached

Theme

👀 View Mode